PRODUCT LITERATURE

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

---

An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its caused
coronavirus disease 2019 (COVID-19) have been reported in China since December 2019. More than
16% of patients developed acute respiratory distress syndrome, and the fatality ratio was about 1%–2%.
No specific treatment has been reported. Herein, we examined the effects of Favipiravir (FPV) versus
Lopinavir (LPV)/ritonavir (RTV) for the treatment of COVID-19.

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Avigan

Specific Detail Info

Engineering xxx (xxxx) xxx

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment